Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

$APLT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $APLT alert in real time by email
SC 13G/A 1 p24-3221sc13ga.htm APPLIED THERAPEUTICS, INC.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
 
Under the Securities Exchange Act of 1934
 
(Amendment No. 1)*
 

 

Applied Therapeutics, Inc.

(Name of Issuer)
 

Common stock, par value $0.0001 per share

(Title of Class of Securities)
 

03828A101

(CUSIP Number)
 

September 30, 2024

(Date of event which requires filing of this statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
 
x Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 03828A10113G/APage 2 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

Vestal Point Capital, LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

- 0 -

6

SHARED VOTING POWER

1,145,000

7

SOLE DISPOSITIVE POWER

- 0 -

8

SHARED DISPOSITIVE POWER

1,145,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,145,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.0%

12

TYPE OF REPORTING PERSON

IA, PN

         

 

CUSIP No. 03828A10113G/APage 3 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

Ryan Wilder

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

- 0 -

6

SHARED VOTING POWER

1,145,000

7

SOLE DISPOSITIVE POWER

- 0 -

8

SHARED DISPOSITIVE POWER

1,145,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,145,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.0%

12

TYPE OF REPORTING PERSON

IN, HC

         

 

CUSIP No. 03828A10113G/APage 4 of 7 Pages

 

 

Item 1(a). NAME OF ISSUER.
   
  The name of the issuer is Applied Therapeutics, Inc. (the "Company").

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
   
  The Company's principal executive offices are located at 545 Fifth Avenue, Suite 1400, New York, NY 10017.

 

Item 2(a). NAME OF PERSON FILING:
   
  This statement is filed by:

 

  (i)

Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Vestal Point Fund and Account; and

 

  (ii) Mr. Ryan Wilder ("Mr. Wilder"), the  Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
   
  The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
   
  The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.

 

Item 2(c). CITIZENSHIP:
   
  The Investment Manager is a Delaware limited partnership.  Mr. Wilder is a citizen of the United States.

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Common stock, par value $0.0001 per share (the "Common Stock").

 

Item 2(e). CUSIP NUMBER:
   
  03828A101

 

 

CUSIP No. 03828A10113G/APage 5 of 7 Pages

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨

Employee benefit plan or endowment fund in accordance with

Rule 13d-1(b)(1)(ii)(F);

 

  (g) x

Parent holding company or control person in accordance with

Rule 13d-1(b)(1)(ii)(G);

  (h) ¨

Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) ¨

Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

 

  (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution: ____________________________

 

Item 4. OWNERSHIP.
   
  The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
   
  The percentages set forth herein are calculated based upon 114,846,271 shares of Common Stock outstanding as of August 6, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 7, 2024.

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
  If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ý

 

 

CUSIP No. 03828A10113G/APage 6 of 7 Pages

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  See Item 2(a).  The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.

 

Item 10. CERTIFICATION.
   
  Each of the Reporting Persons hereby makes the following certification:
   
  By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP No. 03828A10113G/APage 7 of 7 Pages

 

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: November 14, 2024

 

 

VESTAL POINT CAPITAL, LP
By: VESTAL POINT CAPITAL, LLC, its general partner  
     
By: /s/ Ryan Wilder  
Name: Ryan Wilder  
Title: Chief Investment Officer and Managing Partner  
     
     
/s/ Ryan Wilder  
Ryan Wilder  

 

 

Get the next $APLT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APLT

DatePrice TargetRatingAnalyst
12/23/2024Outperform → Mkt Perform
William Blair
12/2/2024$13.00 → $2.00Buy → Neutral
UBS
11/29/2024$12.00 → $4.00Outperform → Sector Perform
RBC Capital Mkts
7/31/2024Outperform
William Blair
3/26/2024$12.00Outperform
RBC Capital Mkts
2/22/2024$12.00Outperform
Leerink Partners
1/4/2022$44.00 → $7.00Overweight → Equal-Weight
Barclays
8/27/2021$10.00Neutral → Sell
Goldman Sachs
More analyst ratings

$APLT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

    NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

    NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APLT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$APLT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$APLT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$APLT
SEC Filings

See more

$APLT
Leadership Updates

Live Leadership Updates

See more
  • Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

    NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

    NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APLT
Financials

Live finance-specific insights

See more
  • Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

    Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p<0.001) Highly statistically significant effects on the CMT Health Index (CMT-HI) patient reported outcome measure (p=0.01), with benefit of govorestat on categories of lower limb function, mobility, fatigue, pain, sensory function, and upper limb function Company plans to request a pre-NDA meeting with the neurology division of the US FDA regarding potential approval based on current data Company to host investor conference call and webcast today at 8:3

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

    Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker dataGovorestat treatment improved activities of daily living, behavior, cognition, fine motor skills, adaptive skills and tremor vs. placeboCompany plans to request a pre-NDA meeting with the FDA as soon as possible to discuss a potential NDA submission in second half of 2023; plans to submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in mid-2023  NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

    The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and EuropeAT-007 reduced sorbitol by a mean of 52%, or approximately 16,000 ng/ml, over a 90 day period, which was highly statistically significant vs. placebo (p<0.001)Company to host conference call to discuss results at 8:30am Eastern NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medi

    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APLT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more